CDI Labs Announces the Addition of Its SARS-CoV-2 (COVID19) Assay Platform

PR Newswire | August 21, 2020

CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform.  The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all known viruses as well as epitope level data on COVID19 antibodies. In addition, CDI has added the COVID19 S and N proteins to CDI's HuProtTM proteome microarray. CDI's VirScan is the first commercial use of the incredibly powerful PhIP-seq technology (Xu, George J et al. SARS-COV-2 "Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome." Science (New York, N.Y.) vol. 348,6239 (2015): aaa0698. doi:10.1126/science.aaa0698). These p

Spotlight

Melitza Cornejo es bióloga, maestrante del Programa de Biotecnología Molecular de la Universidad Nacional de Tumbes, financiado por CIENCIACTIVA.

Spotlight

Melitza Cornejo es bióloga, maestrante del Programa de Biotecnología Molecular de la Universidad Nacional de Tumbes, financiado por CIENCIACTIVA.

Related News

CELL AND GENE THERAPY

Bio-Techne Signs License Agreement with Luminary Therapeutics for the Use of TcBuster™ for the Manufacturing of Gene-modified Cell Therapies

Bio-Techne | February 25, 2021

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBuster in their LMY-920 program, a BAFF-CAR-T product. Luminary Therapeutics intends to file an IND with the FDA later this calendar year. "This agreement with Luminary Therapeutics brings Bio-Techne's cutting-edge TcBuster system one step closer to delivering gene-modified cell therapies," said Dave Eansor, President of Bio-Techne's Protein Sciences Segment. "With this license agreement, Bio-Techne will increase its presence as a key player in the cell and gene therapy market." About Luminary Therapeutics Luminary Therapeutics is a pre-clinical cell therapy company developing next generation non-viral autologous cell treatments for cancers and autoimmune diseases. Luminary's primary focus is to develop CAR T and other next generation cell therapies that address the antigen escape issue present with existing therapies. Luminary utilizes Bio-Techne's TcBuster™ transposon technology to reduce safety concerns, costs, and time delays associated with viral based cell therapies. Located in Minneapolis, Luminary's team is comprised of cellular therapy veterans, industry leaders, and world-renowned cancer geneticist leaders from top biotech and consulting organizations. Luminary seeks novel next generation licensing opportunities with strong intellectual property (IP) for the treatment of solid tumors and in underserved disorders.

Read More

MEDTECH

Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million

Tavotek | November 19, 2021

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addition, the funding will also be used to accelerate the CMC and IND development of multiple other oncology pipelines and the development of the company's multicyclic intracellular peptide (MIP) programs. Tavotek Biotherapeutics, established in early 2019, is committed to using innovation to improve the well-being of patients with unmet medical needs. The company has two R&D centers: one in Lower Gwynedd, Pennsylvania and another in Suzhou, China. The core team members have decades of successful drug development experiences at multinational pharmaceutical firms (Johnson & Johnson, Abbott/Abbvie, GlaxoSmithKline and Eli Lilly) which include many blockbuster drugs with annual sales of more than $1 billion. Tavotek's research platforms are built upon three breakthrough technologies: TavoSelect (an innovative Phage Display Library that generates conformational selective human full-length and single domain antibodies); TavoPrecise (a differentiated engineering platform for next generation tissue-specific biologics); and TavoMIP (a multicyclic peptide platform that makes undruggable targets more accessible). With the new infusion of capital, Tavotek is developing novel biologics targeting oncology and autoimmune diseases for patients. The company plans to bring multiple innovative antibodies into human clinical trials in 2022. About Tavotek Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases.

Read More

INDUSTRY OUTLOOK

RegeneRx Licensee Acquired by Korean Biopharmaceutical Group

RegeneRx Biopharmaceuticals, Inc. | September 28, 2021

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration), announced that GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company that includes six biopharmaceutical and financial subsidiaries in Korea and the U.S. GtreeBNT announced that as part of its acquisition the company would issue approximately US$80 million of new stock and convertible bonds to HLB Group to fund ongoing programs. The new capital should speed up the clinical trials currently in progress and allow the company to focus on new drug approval. RGN-259 will remain a priority for the company. HLB's recommended executives are expected to be appointed at the general meeting scheduled for October 29, 2021. Won Yang, the current CEO of GtreeBNT, is expected to remain as the chief research officer and continue to lead the development of new drugs after the acquisition. RegeneRx has scheduled its 2021 Annual Stockholder Meeting for November 10, 2021 and hopes to have additional details on the acquisition and its effect on GtreeBNT's clinical development activities and timing related to RGN-259 and RGN-137, products developed for the treatment of dry eye syndrome, neurotrophic keratitis, and epidermolysis bullosa. The fact that GtreeBNT will receive a significant capital infusion related to the transaction, we believe, should benefit the development of the products we licensed to the company. As soon as practicable after we receive any new information from the new management related to our products we will update our stockholders. - J.J. Finkelstein, president and chief executive. About RegeneRx Biopharmaceuticals, Inc. RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair, and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac/neuro and dermal indications, four active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and the EU, and has patents and patent applications covering its products in many countries throughout the world.

Read More